Frequently Asked Questions on the WHO Rapid Communication: key changes to the treatment of multidrug- and rifampicin-resistant TB
The World Health Organization (WHO) in collaboration with the Stop TB Partnership’s Global Drug Facility, the Global Fund to Fight AIDS, Tuberculosis and Malaria and the United States Agency for International Development have developed a set of frequently asked questions (and answers) in response to inquiries on upcoming WHO policy recommendations.
The document, has also been prepared in consultation with other key stakeholders and members of the Task Force convened to assist Member States in the planning and preparation for a smooth transition towards the implementation of the new treatment recommendations.
Access the document here.
- WHO Rapid Communication: Key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB)